Co-founded in 2016 by 2 PhD molecular biologists, one of them with over 26 year experience in the aptamer field, the French start-up develops biotechnological products. Its main activity is dedicated to the selection, characterization, optimization and functionalization of custom oligonucleotide aptamers, which are usually called nucleic acid antibodies. Very few companies in the world can develop such aptamer-based tools, in this emerging market.
The French start-up employs engineers, PhDs and post-docs and already deals with foreign partners. More than 75 % of the company's turnover came from international sales in 2020. It is currently developing collaborative projects with academic laboratories and R&D departments of Pharmaceutical, Diagnostic and Agri-food companies worldwide.
Aptamers bind with high affinity to any target of interest: small molecule, protein, peptide, toxin, virus, cell, etc. They represent an alternative to monoclonal antibodies as diagnostic probes, analytical tools or therapeutic agents. In this way, aptamer-based tools allow the rapid detection, quantification or capture of chemical or biological entities as biomarkers, metabolites, drugs, pollutants, virus, cells, ...
Aptamers used by biologists and chemists can be developed by the French start-up either as DNA (Deoxyribonucleic acid), RNA (ribonucleic acid) or chemically-modified RNA (2'F) oligonucleotides. The start-up develops both: first generation aptamers identified through the standard SELEX procedure (Systematic Evolution of Ligands by Exponential Enrichment process), and second generation aptamers through its switching technology NOVAswitch.
The aptamer-based tools obtained with the French SME method show the advantages of so-called “chemical antibodies” i.e. a strong affinity for their cognate ligand and a high specificity of recognition.
The French start-up is expanding fast and is looking for new partners worldwide, to collaborate on new or existing projects.
The French company collaborates with partners under different scenari:
The French company provides its know-how and human and technical resources to co-develop an aptamer with the partner's R&D team. The collaboration is based on a technical cooperation agreement.
MANUFACTURING AGREEMENTS :
• The French company provides the aptamer-based solution according to the partner's specifications. It allows the potential partner to subcontract the aptamer production while designing a new product or service.
• The French company produces a turnkey solution, involving aptamer-based biosensors, to meet the potential partner's needs. The solution development is then entirely backed by the French campany.